Results of PLATO trial published in JCO

The results of the PLATO trial have just been published in the Journal of Clinical Oncology (JCO). … READ MORE …

The potential for use of enzalutamide in HSPC: an update

We note that Pfizer and Astellas have recently modified the protocols for two large, international, randomized, Phase III clinical trials to see if they can get earlier results that might affect the potential for use of enzalutamide (Xtandi) in some groups of men with hormone-sensitive prostate cancer (HSPC). … READ MORE …

Evolution in the management of nmCRPC

With the relatively recent approvals of apalutamide (Erleada) and enzalutamide (Xtandi) for the treatment of non-metastatic, castration-resistant prostate cancer (nmCRPC), we are seeing intense discussion within the urologic oncology and medical oncology communities about the appropriate treatment of patients with this category of prostate cancer. … READ MORE …

Evolutions in the treatment of nmCRPC — redux

So at the Genitourinary Cancers Symposium in San Francisco today we were presented with full reports on the SPARTAN trial and the PROSPER trial by Drs. Eric Small and Maha Hussain, respectively. … READ MORE …

Evolutions in the treatment of nmCRPC

So we now have news reports and abstracts telling us what the top-line results of the SPARTAN trial and the PROSPER trial are in the treatment of men with non-metastatic, castration-resistant prostate cancer (nmCRPC). … READ MORE …

FDA gives priority review status to NDA for apalutamide

Apparently the US Food and Drug Administration (FDA) will give a priority review to apalutamide (formerly known as ARN-509), based on data from the Phase III SPARTAN  trial in men with non-metastatic castration-resistant prostate cancer (nmCRPC). … READ MORE …

Enzalutamide treatment and risk for seizures

The “Warnings and Precautions” section of the product prescribing information for enzalutamide (Xtandi) includes the following statement: … READ MORE …